º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Tech

Newcastle biotech business Atelerix secures more than £425,000 in investment

The Newcastle University spin-out is set to bring its revolutionary cell preservation tech to market

Debra Leeves, chair of Atelerix(Image: Insight Photography Ltd)

A North East biotech business is set to bring a ground-breaking cell preservation product to market after raising more than £425,000 in investment.

Newcastle University spin-out Atelerix was launched in 2017 by co-founders Professor Che Connon, Dr Steve Swioklo and Dr Mick McLean.

The company aims to revolutionise cell preservation by changing the way cells and tissues are stored and transported. It has raised £425,574 in investment to help fully commercialise its product and bring it to market.

Read more: go here for more North East business news

Based in the Biosphere building at Newcastle Helix, the firm says that conventional ways of freezing and thawing cells and tissues through cryogenics can be hugely damaging, and that cells often die or change their function in the process.

To counter the issue, Atelerix has developed technology that encapsulates the cells in an alginate gel, preserving them at room temperature for up to two weeks.

It means cells are kept safe and can be delivered across the world undamaged when they reach their destination. The gel is simply dissolved when the cells are needed.

Debra Leeves, chair of Atelerix, is leading the commercialisation of the gel to be used for drug discovery and testing, as well as for cells to be used as the starting material for therapies.